Marcie Riches MD, MS of the University of North Carolina Lineberger Comprehensive Cancer Center discusses chronic GVHD and how it differs from acute GVHD. Treatment options vary, depending on location of GVHD and severity.
To view transcript go to [ Ссылка ]
In this video, the speaker discusses:
• Approximately 50% of patients who have an allogeneic transplant (transplant using donor cells) develop chronic GVHD
• Chronic GVHD most often affects the skin, eyes and mouth, but it can affect virtually any organ in the body
• Most people experience only mild or moderate GVHD, but in some cases, chronic GVHD lasts for many years
• There are two types of treatment: systemic, which affects the entire body, and topical, which only affects the area where GVHD is active
Steroids are the mainstay of systemic treatment and have many long-term side effects
This video is a recording of the workshop conducted at the 2019 Celebrating a Second Chance at Life Survivorship Symposium.
Presentation is 45-minutes, followed by a 15-minute Q & A session.
Meet presenter:
Marcie Riches: [ Ссылка ]
WHO WE ARE: BMT InfoNet is dedicated to providing patients and their loved ones with emotional support and high quality, easy-to-understand information about blood stem cell transplants (bone marrow, peripheral blood and cord blood) and other cellular therapies.
Whether you are just beginning your transplant or cellular therapy journey, or learning to manage the joys and challenges of survivorship, BMT InfoNet is here to help before, during and after treatment.
Our goal is to empower you with credible information and emotional support, so that you can take a more active role in decisions affecting your health.
[ Ссылка ]
VISIT US ON SOCIAL MEDIA:
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
